文献速递间质性肺疾病呼吸危重症与机械通气

间充质基质细胞外泌体通过巨噬细胞免疫调节改善实验性支气管肺发育不良并恢复肺功能

Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

本研究在新生小鼠高氧(75% O2)支气管肺发育不良(BPD)模型中,于出生后第4天给予人MSC来源外泌体(MSC-exo)治疗,第7天回到室内空气,评估肺参数。结果显示MSC-exo可减轻高氧所致肺泡简化、纤维化、肺血管重塑和肺动脉高压,改善肺功能,其机制与调节肺巨噬细胞表型(抑制M1、促进M2样)相关。

要点

  • MSC-exo治疗可减轻高氧诱导的新生小鼠BPD样肺损伤和肺功能损害。
  • MSC-exo可减少高氧相关纤维化、肺血管重塑和肺动脉高压。
  • MSC-exo作用与调节肺巨噬细胞M1/M2表型平衡相关。

核心结论

  • MSC-exo治疗可减轻高氧相关炎症并改变高氧肺转录组,从而缓解实验性BPD、改善肺功能、减少纤维化和肺血管重塑并改善肺动脉高压。
  • MSC-exo的作用机制与调节肺巨噬细胞表型相关。

研究设计与样本

  • 从人MSC培养条件培养基中分离外泌体。
  • 新生小鼠暴露于高氧(75% O2),于出生后第4天给予外泌体治疗,第7天返回室内空气。
  • 治疗组与相应对照组于出生后第7、14或42天取材评估肺参数。

主要发现

  • 高氧暴露小鼠出现明显的肺泡简化、纤维化和肺血管重塑,MSC-exo治疗可有效改善。
  • 肺功能检测和肺动脉高压评估显示MSC-exo治疗后功能改善。
  • 肺mRNA测序显示MSC-exo对高氧诱导的炎症和免疫反应相关基因表达产生多效性影响。
  • MSC-exo在体外和体内均调节巨噬细胞表型平衡,抑制促炎M1状态并增强抗炎M2样状态。

临床怎么用

  • 临床前证据提示MSC-exo可能作为BPD的候选治疗策略,但尚需临床研究验证。
  • 其作用与巨噬细胞免疫调节相关,提示免疫微环境调控可能是BPD干预方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Mesenchymal stem/stromal cell (MSC) therapies have shown promise in preclinical models of pathologies relevant to newborn medicine, such as bronchopulmonary dysplasia (BPD). We have reported that the therapeutic capacity of MSCs is comprised in their secretome, and demonstrated that the therapeutic vectors are exosomes produced by MSCs (MSC-exos). OBJECTIVES: To assess efficacy of MSC-exo treatment in a preclinical model of BPD and to investigate mechanisms underlying MSC-exo therapeutic action. METHODS: Exosomes were isolated from media conditioned by human MSC cultures. Newborn mice were exposed to hyperoxia (HYRX; 75% O2), treated with exosomes on Postnatal Day (PN) 4 and returned to room air on PN7. Treated animals and appropriate controls were harvested on PN7, -14, or -42 for assessment of pulmonary parameters. MEASUREMENTS AND MAIN RESULTS: HYRX-exposed mice presented with pronounced alveolar simplification, fibrosis, and pulmonary vascular remodeling, which was effectively ameliorated by MSC-exo treatment. Pulmonary function tests and assessment of pulmonary hypertension showed functional improvements after MSC-exo treatment. Lung mRNA sequencing demonstrated that MSC-exo treatment induced pleiotropic effects on gene expression associated with HYRX-induced inflammation and immune responses. MSC-exos modulate the macrophage phenotype fulcrum, suppressing the proinflammatory "M1" state and augmenting an antiinflammatory "M2-like" state, both in vitro and in vivo. CONCLUSIONS: MSC-exo treatment blunts HYRX-associated inflammation and alters the hyperoxic lung transcriptome. This results in alleviation of HYRX-induced BPD, improvement of lung function, decrease in fibrosis and pulmonary vascular remodeling, and amelioration of pulmonary hypertension. The MSC-exo mechanism of action is associated with modulation of lung macrophage phenotype.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Willis GR, Fernandez-Gonzalez A, Anastas J, et al. Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. Am J Respir Crit Care Med. 2018. PMID: 28853608. doi:10.1164/rccm.201705-0925OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。